@article{3220552,
    title = "A Real-world Multicenter Prospective Study of Everolimus in Pancreatic Neuroendocrine Tumors: The ‘PROTOR’ Study",
    author = "Kaltsas, G. and Andreadis, C. and Kosmidis, P. and Mavroudis, D. and Pazaitou-Panayiotou, K. and Vaslamatzis, M. and Athanasiadis, I.",
    journal = "ANTICANCER RESEARCH",
    year = "2022",
    volume = "42",
    number = "4",
    pages = "1941-1948",
    publisher = "International Institute of Anticancer Research",
    issn = "0250-1291",
    doi = "10.21873/anticanres.15672",
    keywords = "angiopeptin;  aspartate aminotransferase;  everolimus;  gamma glutamyltransferase;  glycosylated hemoglobin;  octreotide;  somatostatin derivative;  sunitinib;  everolimus, ablation therapy;  adult;  Article;  artificial embolization;  cancer radiotherapy;  cancer staging;  clinical article;  controlled study;  diabetes mellitus;  distal pancreatectomy;  drug dose reduction;  dyslipidemia;  female;  follow up;  glucose blood level;  Greece;  human;  hypertriglyceridemia;  inoperable cancer;  Kaplan Meier method;  male;  metastasis resection;  middle aged;  multicenter study;  observational study;  overall response rate;  pancreas islet cell tumor;  progression free survival;  prospective study;  side effect;  stomatitis;  treatment duration;  clinical trial;  neuroendocrine tumor;  pancreas tumor;  pathology;  prospective study, Everolimus;  Humans;  Kaplan-Meier Estimate;  Middle Aged;  Neuroendocrine Tumors;  Pancreatic Neoplasms;  Prospective Studies",
    abstract = "Background/Aim: Pancreatic neuroendocrine tumors (panNETs) are rare neoplasms with challenging disease management. We aimed to evaluate the progression-free survival (PFS) and overall response rate (ORR) in chemotherapy-naïve patients with unresectable or metastatic Grade (G) 1-2 panNETs treated with everolimus in the routine care in Greece. Patients and Methods: This was a multicenter, prospective, observational study. Eligible patients were recently (≤4 weeks) initiated on treatment with everolimus and were followed for up to 48 months. Results: Nineteen eligible patients (mean age 55.1 years) were enrolled. All patients had metastatic disease and 84.2% had G2 panNET. Everolimus was initiated in combination with somatostatin analogues in 84.2% of the patients. The mean everolimus treatment duration was 21.5 months. The median Kaplan-Meier-estimated PFS was 20.4 months (95% confidence interval=14.1-41.5). The ORR was 27.8%. The rate of everolimus-related adverse events was 84.2% (Grade ≥3: 31.6%). Conclusion: Everolimus displayed clinical benefit and a predictable safety profile in pancreatic neuroendocrine tumors. © 2022 International Institute of Anticancer Research. All rights reserved."
}